BREAST CANCER PREVENTION





  • References PMID 25423325, PMID 25210448, PMID 10874566
SERM ACTIVITY TABLE
SERM Product Endometrium Vagina Breast Bone
formation
Hypothalamus
Bazedoxifene Duavee® Neutral to
Antagonist
No data Neutral to
Antagonist
Agonist ?
Clomiphene Clomid® Antagonist ? ? Agonist Antagonist
Ospemifene Osphena® Neutral to
Partial agonist
Agonist Antagonist Agonist ?
Raloxifene Evista® Neutral to
Partial agonist
Neutral Antagonist Agonist ?
Tamoxifen Nolvadex® Neutral to
Agonist
Agonist Antagonist Agonist ?


















  • Data expressed as cases/1000 women/year
  • Data is from the BCPT trial
Tamoxifen Risks
(cases/1000 women/year)
Outcome Tamoxifen Placebo
Endometrial adenocarcinoma 2.20 0.71
Uterine sarcoma 0.17 0.04
Stroke 1.43 1.0
Pulmonary embolism 0.75 0.25
Deep vein thrombosis 1.26 0.79
Cataract 25.41 22.51

  • Data expressed as % of women with outcome/year
  • Data is from the RUTH trial (N=10,101; median follow-up 5.6 years)
Raloxifene Risks
(% of women with outcome/year)
Outcome Raloxifene Placebo
Death from stroke 0.22 0.15
Stroke 0.95 0.86
Pulmonary embolism 0.14 0.09
Deep vein thrombosis 0.24 0.18

  • Reference: Tamoxifen Package Insert
  • Data is from the BCPT trial
Tamoxifen side effects
Side effect Tamoxifen Placebo
Hot flashes 80% 68%
Vaginal discharges 55% 35%
Vaginal bleeding 23% 22%
Mood changes 11.6% 10.8%
Infection/sepsis 6.0% 5.1%
Constipation 4.4% 3.2%
Hair loss 5.2% 4.4%
Skin changes 5.6% 4.7%

  • Reference: Raloxifene Package Insert
  • Side effects that occurred with a difference between placebo of < 1% are not included
Raloxifene side effects
Side effect Raloxifene Placebo
Joint pain 15.5% 14%
Flu syndrome 13.5% 11.4%
Hot flashes 9.7% 6.4%
Leg cramps 7% 3.7%
Uterine disorders
(not defined)
3.3% 2.3%